Delivery routes matter: Safety and efficacy of intratumoral immunotherapy

Intratumoral immunotherapy for early stage solid tumors

(2020) Wan Xing Hong et al.   CLINICAL CANCER RESEARCH

Safe eradication of large established tumors using neovasculature‐targeted tumor necrosis factor‐based therapies

(2020) Leander Huyghe et al.   EMBO Molecular Medicine

Intratumor injection of CCL21-coupled vault nanoparticles is associated with reduction in tumor volume in an in vivo model of glioma

(2020) Brittany L. Voth et al.   JOURNAL OF NEURO-ONCOLOGY

Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager

(2019) Jana de Sostoa et al.   Journal for ImmunoTherapy of Cancer

Two roads for oncolytic immunotherapy development

(2019) Howard L. Kaufman et al.   Journal for ImmunoTherapy of Cancer

Antibody–Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity

(2019) Dario Neri   Cancer Immunology Research

Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs

(2019) Susannah L. Hewitt et al.   Science Translational Medicine

Local delivery of OX40L, CD80, and CD86 mRNA kindles global anti-cancer immunity.

(2019) Ole Audun Werner Haabeth et al.   CANCER RESEARCH

Induction of cell fusion/apoptosis in anaplastic thyroid carcinoma in orthotopic mouse model by urokinase‐specific oncolytic Sendai virus

(2019) Yoshihiro Miyagawa et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Targeted antibody and cytokine cancer immunotherapies through collagen affinity

(2019) Jun Ishihara et al.   Science Translational Medicine

A toll-like receptor agonist mimicking microbial signal to generate tumor-suppressive macrophages

(2019) Yanxian Feng et al.   Nature Communications

Coxsackievirus Type B3 is A Potent Oncolytic Virus against KRAS-Mutant Lung Adenocarcinoma

(2019) Haoyu Deng et al.   Molecular Therapy-Oncolytics

Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds

(2019) Venkatesh Sivanandam et al.   Molecular Therapy-Oncolytics

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer

(2019) Juan Deng et al.   OncoTargets and Therapy

Therapeutic strategies for the costimulatory molecule OX40 in T-cell mediated immunity

(2019) Yu Fu et al.   Acta Pharmaceutica Sinica B

Repurposing the yellow fever vaccine for intratumoral immunotherapy

(2019) Maria Angela Aznar et al.   EMBO Molecular Medicine

Engineering Newcastle disease virus as oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokines

(2019) Gayathri Vijayakumar et al.   JOURNAL OF VIROLOGY

Intratumoral Immunotherapy—Update 2019

(2019) Omid Hamid et al.   ONCOLOGIST

Toxicities associated with checkpoint inhibitors—an overview

(2019) Laura Spiers et al.   RHEUMATOLOGY

Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer

(2019) Jenna H. Newman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion

(2019) Nicholas C. DeVito et al.   Frontiers in Immunology

Immunogenic cell death induced by a new photodynamic therapy based on photosens and photodithazine

(2019) Victoria D. Turubanova et al.   Journal for ImmunoTherapy of Cancer

Overcoming Physiological Barriers to Nanoparticle Delivery—Are We There Yet?

(2019) Oliver S. Thomas et al.   Frontiers in Bioengineering and Biotechnology

Necroptosis: a regulated inflammatory mode of cell death

(2018) Yogesh K. Dhuriya et al.   Journal of Neuroinflammation

mRNA vaccines — a new era in vaccinology

(2018) Norbert Pardi et al.   NATURE REVIEWS DRUG DISCOVERY

Complex role of NK cells in regulation of oncolytic virus–bortezomib therapy

(2018) Yangjin Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters

(2018) Colin J. McKinlay et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

In situ vaccination: Harvesting low hanging fruit on the cancer immunotherapy tree

(2018) Mee Rie Sheen et al.   Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology

Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma

(2018) Mark R. Albertini et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice

(2018) Ole A. W. Haabeth et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes

(2018) Lien Van Hoecke et al.   Nature Communications

Nanoparticle-Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses

(2018) Lutz Nuhn et al.   ADVANCED MATERIALS

42PA phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors

(2018) J K Schwarze et al.   ANNALS OF ONCOLOGY

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

(2018) A Marabelle et al.   ANNALS OF ONCOLOGY

Administration of Dendritic Cells and Anti-PD-1 Antibody Converts X-ray Irradiated Tumors Into Effective In situ Vaccines

(2018) Yuzi Wang et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend

(2018) Hanne Locy et al.   Frontiers in Immunology

Thermosensitive Gel–Based Formulation for Intratumoral Delivery of Toll-Like Receptor 7/8 Dual Agonist, MEDI9197

(2017) Amir Fakhari et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses

(2017) Kapil Bahl et al.   MOLECULAR THERAPY

Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals

(2017) Colin J. McKinlay et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer

(2017) Julia Tchou et al.   Cancer Immunology Research

Indicators of responsiveness to immune checkpoint inhibitors

(2017) Bradley D. Shields et al.   Scientific Reports

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

(2016) Robert H. I. Andtbacka et al.   ANNALS OF SURGICAL ONCOLOGY

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN

(2016) Laura Q.M. Chow et al.   CLINICAL CANCER RESEARCH

Immunocytokines for cancer treatment: past, present and future

(2016) Dario Neri et al.   CURRENT OPINION IN IMMUNOLOGY

TGF-β Signaling in Cancer

(2016) Viqar Syed   JOURNAL OF CELLULAR BIOCHEMISTRY

Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma

(2016) Sofie Wilgenhof et al.   JOURNAL OF CLINICAL ONCOLOGY

Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally

(2016) M. Angela Aznar et al.   JOURNAL OF IMMUNOLOGY

GIFT4 fusokine converts leukemic B cells into immune helper cells

(2016) Jiusheng Deng et al.   Journal of Translational Medicine

Vaccination with Necroptotic Cancer Cells Induces Efficient Anti-tumor Immunity

(2016) Tania Løve Aaes et al.   Cell Reports

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy

(2016) Hasan Rehman et al.   Journal for ImmunoTherapy of Cancer

OX40, OX40L and Autoimmunity: a Comprehensive Review

(2015) Gwilym J. Webb et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Cytokines

(2015) Thulasi Ramani et al.   INTERNATIONAL JOURNAL OF TOXICOLOGY

Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines

(2015) Mikhail O Durymanov et al.   Theranostics

Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells

(2015) S. Van Lint et al.   Cancer Immunology Research

Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity

(2015) Kevin Van der Jeught et al.   Oncotarget

Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy

(2014) Francesca Pretto et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula

(2014) Sandra Van Lint et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The ReNAissanCe of mRNA-based cancer therapy

(2014) Sandra Van Lint et al.   Expert Review of Vaccines

Toll-Like Receptor Signaling Pathways

(2014) Takumi Kawasaki et al.   Frontiers in Immunology

TLR Agonists as Modulators of the Innate Immune Response and Their Potential as Agents Against Infectious Disease

(2014) Edin J. Mifsud et al.   Frontiers in Immunology

A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients

(2013) S. Wilgenhof et al.   ANNALS OF ONCOLOGY

Many faces of DAMPs in cancer therapy

(2013) O Krysko et al.   Cell Death & Disease

Preclinical Evaluation of TriMix and Antigen mRNA-Based Antitumor Therapy

(2012) S. Van Lint et al.   CANCER RESEARCH

Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 Kinase

(2012) Liming Sun et al.   CELL

Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis

(2012) J. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

(2011) Mark S. Diamond et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo

(2011) C Cocco et al.   LEUKEMIA

Tumor masses support naive T cell infiltration, activation, and differentiation into effectors

(2010) Elizabeth D. Thompson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Single-Step Antigen Loading and Activation of Dendritic Cells by mRNA Electroporation for the Purpose of Therapeutic Vaccination in Melanoma Patients

(2009) A. Bonehill et al.   CLINICAL CANCER RESEARCH

The significance of OX40 and OX40L to T-cell biology and immune disease

(2009) Michael Croft et al.   IMMUNOLOGICAL REVIEWS

Enhancing the T-cell Stimulatory Capacity of Human Dendritic Cells by Co-electroporation With CD40L, CD70 and Constitutively Active TLR4 Encoding mRNA

(2008) Aude Bonehill et al.   MOLECULAR THERAPY